Regulator: CECMED (Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos)
The Dominican Republic is developing its clinical research infrastructure with DIGEMAPS (historically referenced as CECMED) overseeing medical device registration and clinical trials. The country follows a risk-based classification system (I, IIa, IIb, III) with a 240-working-day approval timeline for device registration. A local Authorized Representative is mandatory for foreign manufacturers.
DIGEMAPS governs medical device registration following a risk-based classification (I, IIa, IIb, III). The approval timeline is a study-specific timeline (we confirm it per protocol). SaMD products must include IEC 62304 compliance and cybersecurity documentation. A renewable sanitary registration is required.
FDA accepts Dominican Republic clinical data under 21 CFR 812.28 when studies follow ICH-GCP. The country's growing research capacity and alignment with international standards make it a developing option for generating FDA-submissible data.
Varies by study; we confirm per protocol for a complete registration.
Yes, a local Authorized Representative (AR) is mandatory for all foreign manufacturers.
Yes, SaMD requires mandatory approval including IEC 62304 compliance and cybersecurity reports.
Sanitary registrations are renewable; we confirm the current validity period with DIGEMAPS for each product.
Yes, when studies follow ICH-GCP and ISO 14155 standards.
All Latin America regulatory guides · Book a free 30-min strategy call